Arnaud Claire, Braunersreuther Vincent, Mach François
Division of Cardiology, Foundation for Medical Research, Faculty of Medicine, Geneva University Hospital, 1211 Geneva, Switzerland.
Trends Cardiovasc Med. 2005 Aug;15(6):202-6. doi: 10.1016/j.tcm.2005.07.002.
Over the past decade, a large number of studies reported a prominent role of inflammation and immune response in atherosclerosis. Thus, therapeutic strategies to reduce inflammation could exert beneficial effects in the prevention of atherosclerosis progression. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) have demonstrated their capacity to greatly reduce coronary morbidity and mortality in both primary and secondary intervention trials. Furthermore, originally described as the most efficient drugs to reduce serum cholesterol, recent reports suggest that statins also confer cardiovascular benefits by their ability to modulate immuno-inflammatory processes. This review summarizes in vitro and in vivo evidence of immunomodulatory properties of statins.
在过去十年间，大量研究报告了炎症和免疫反应在动脉粥样硬化中发挥的重要作用。因此，减轻炎症的治疗策略可能对预防动脉粥样硬化进展产生有益影响。3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）已在一级和二级干预试验中证明其有能力大幅降低冠心病的发病率和死亡率。此外，他汀类药物最初被描述为降低血清胆固醇最有效的药物，最近的报告表明，他汀类药物还通过调节免疫炎症过程的能力带来心血管益处。这篇综述总结了他汀类药物免疫调节特性的体外和体内证据。
